Skip to content

Nuvalent, Inc. NUVL Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$646.64M+113%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$647.86M+68.8%
Exelixis logo
ExelixisEXEL
$2.59B-8.6%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$2.25B-4.7%
Incyte logo
IncyteINCY
$7.34B+27.7%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s total liabilities & equity?
Nuvalent, Inc. (NUVL) reported total liabilities & equity of $1.33B in Q1 2026.
How has Nuvalent, Inc.'s total liabilities & equity changed year-over-year?
Nuvalent, Inc.'s total liabilities & equity increased by 20.4% year-over-year, from $1.11B to $1.33B.
What is the long-term trend for Nuvalent, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s total liabilities & equity has grown at a 165.8% compound annual growth rate (CAGR), from $10.65M to $1.41B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.